Global X Cloud Computing ETF vs Merck & Co., Inc. — how do they compare? Global X Cloud Computing ETF trades at $27.79, while Merck & Co., Inc. trades at $133.35 (market cap $321.77B). The key difference: Merck & Co., Inc. pays a 2.61% dividend while Global X Cloud Computing ETF pays none. Which is the better fit depends on your goals.
| CLOU | MRK | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $28.09 | $131.84 |
52-Week Low | $17.60 | $77.60 |
Market Cap | — | $321.77B |
Enterprise Value | — | $368.53B |
Dividend Yield | — | 2.61% |
Signals from Pluang's Aura AI — not financial advice
CLOU, the Global X Cloud Computing ETF, trades at $27.77, down 1.14% today, with technical indicators showing a bullish trend from moving averages but overbought signals from RSI levels above 83. The ETF offers diversified exposure to cloud computing stocks like Snowflake and Datadog, benefiting from long-term growth drivers in digital transformation.
The outlook remains positive due to strong non-AI growth factors and resilient subscription revenues, though risks include sector volatility and competitive pressures. Analyst sentiment is bullish, with buy ratings highlighting growth potential beyond short-term hype.
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
Trailing returns across standard periods
Latest headlines on both assets
CLOU is a thematic ETF that invests in companies leading the cloud revolution. It targets providers of SaaS, PaaS, and IaaS, including major firms like Salesforce, Akamai, and Shopify that drive modern digital infrastructure.
Read more on CLOU →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →